DexCom, Inc. vs Levi Strauss & Co. — how do they compare? DexCom, Inc. trades at $89.2 (market cap $33.79B), while Levi Strauss & Co. trades at $22.95 (market cap $8.75B). The key difference: DexCom, Inc. is far larger — about 3.9× Levi Strauss & Co.'s market cap, and Levi Strauss & Co. pays a 2.81% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | LEVI | |
|---|---|---|
Market Cap | $33.79B | $8.75B |
Sector | Health | Consumer Cyclical |
52-Week High | $89.53 | $25.53 |
52-Week Low | $54.84 | $17.92 |
Enterprise Value | $33.24B | $10.07B |
Dividend Yield | — | 2.81% |
Trailing returns across standard periods
Latest headlines on both assets
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →